APA (7th ed.) Citation

G, F., VI, S., L, G., DF, A., N, P., V, S., . . . W, C. (2026). Immune Response and Safety of Anti-NeuGcGM3 Anti-Idiotype Vaccine Racotumomab in Patients With High-Risk Neuroblastoma: An Open-Label, Single-Arm, Multicenter Phase 2 Study in Argentina. Pediatric blood & cancer, e70394. https://doi.org/10.1002/1545-5017.70394

Chicago Style (17th ed.) Citation

G, Felizzia, et al. "Immune Response and Safety of Anti-NeuGcGM3 Anti-Idiotype Vaccine Racotumomab in Patients With High-Risk Neuroblastoma: An Open-Label, Single-Arm, Multicenter Phase 2 Study in Argentina." Pediatric Blood & Cancer 2026: e70394. https://doi.org/10.1002/1545-5017.70394.

MLA (9th ed.) Citation

G, Felizzia, et al. "Immune Response and Safety of Anti-NeuGcGM3 Anti-Idiotype Vaccine Racotumomab in Patients With High-Risk Neuroblastoma: An Open-Label, Single-Arm, Multicenter Phase 2 Study in Argentina." Pediatric Blood & Cancer, 2026, p. e70394, https://doi.org/10.1002/1545-5017.70394.